PULSE YOUR HEALTH

Depression is a global mental health challenge, affecting millions of people every year. While traditional treatments like antidepressants and therapy work for many, some individuals struggle with treatment-resistant depression (TRD). Enter Spravato—a groundbreaking solution offering hope to those who have not found relief with conventional methods. This blog delves into what Spravato is, how it works, and why it’s changing the landscape of mental health treatment. What is Spravato? Spravato is the brand name for esketamine, a prescription nasal spray approved by the U.S. Food and Drug Administration (FDA) in 2019 for adults with treatment-resistant depression. Esketamine is a derivative of ketamine, an anesthetic that has shown rapid antidepressant effects in low doses.  Spravato (esketamine) was developed by Janssen Pharmaceuticals , a subsidiary of Johnson & Johnson . Janssen is known for its focus on innovative treatments across a range of medical fields, including mental h...